Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | SOD1 | P00441 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291240 | 1.00 | CA1 (0.36) | CA1CA2CA4CA9CCR3 | |
| SCHEMBL4291606 | 0.90 | SCN9A (0.38) | SCN9A | |
| SCHEMBL4292524 | 0.88 | LTA4H (0.39) | CCR3PARP1SCN9A | |
| SCHEMBL4284889 | 0.85 | SCN9A (0.40) | SCN9ASOD1 | |
| SCHEMBL3493396 | 0.84 | TEAD1 (0.46) | CA1CA2CA4CA9PARP1 | |
| SCHEMBL8118778 | 0.83 | CXCR4 (0.43) | — | |
| Hydrochloric Acid SCHEMBL4293711 | 0.82 | PARP1 (0.45) | CA1CA2CA4CA9PARP1 | |
| Hydrochloric Acid SCHEMBL4293709 | 0.82 | PARP1 (0.45) | CA1CA2CA4CA9PARP1 | |
| SCHEMBL4282373 | 0.81 | L3MBTL1 (0.47) | CA1CA2CA4CA9PARP1 | |
| SCHEMBL4751897 | 0.81 | L3MBTL1 (0.47) | CA1CA2CA4CA9PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |